https://doi.org/10.1016/s1470-2045(19)30863-0
S
Soo Chin Lee
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
364
Papers
12.5K
Citations
54
h-index
150
i10-index
Soo Chin Lee is an academic researcher from National University of Singapore. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Genomics and Diagnostics & Breast Cancer Treatment Studies. The author has an h-index of 54, co-authored 310 publications.
ORCID: 0000-0002-5835-6419Papers by this author
worksPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2020 · The Lancet Oncology · 865 citations
Discovery of common and rare genetic risk variants for colorectal cancer
2018 · Nature Genetics · 596 citations
https://doi.org/10.1038/s41588-018-0286-6
Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells
2013 · Lab on a Chip · 575 citations
https://doi.org/10.1039/c3lc50617g
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer
2022 · Proceedings of the National Academy of Sciences · 565 citations
https://doi.org/10.1073/pnas.2201376119
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer
2016 · JAMA Oncology · 310 citations
https://doi.org/10.1001/jamaoncol.2016.0237
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
2016 · The Lancet Oncology · 288 citations
https://doi.org/10.1016/s1470-2045(16)00106-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat